Howard Zauberman, the President and CEO of Vision-Sciences, Inc. (VSCI), Interviews with The Wall Street Transcript
67 WALL STREET, New York - August 8, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - Medical Technology Innovation - Medical Equipment Growth Opportunities - Efficient Patient Treatment - Bifurcation in Medical Devices
Companies include: Vision-Sciences Inc. (VSCI) and many more.
In the following excerpt from the Medical Devices Report, the President and CEO of Vision-Sciences, Inc. (VSCI) discusses company strategy and the outlook for this vital industry:
TWST: How is your technology changing medicine today? And I understand it comes with an imaging system connected to it. Your investor presentation seems to indicate the system is less expensive than a conventional system. Why would this be?
Mr. Zauberman: Our technology is changing medicine because it benefits the entire health care system by enhancing safety, increasing productivity and improving health care economics. Here is how. For the patient, there is a lower risk of infection due to our microbial barrier. Often no sedation is required when performing minimally invasive endoscopic procedures with our products, and it is a less costly alternative versus conventional endoscopy. For the physician, all of our procedures are reimbursed and more efficient, allowing for more procedures to be done in a shorter period of time.
For the health care facility, there are lower capital costs because our technology does not require a dedicated facility and staff for reprocessing. Our reprocessing is safe and swift, and patient care is greatly improved. Finally, for the payer, there is a lower cost per procedure because it often does not require sedation, and there is the potential for early detection of high morbidity disease.
The components of the EndoSheath Technology are a scope and an integrated video processor versus multiple scopes and a large video system with conventional endoscopy. Our technology also costs about one-third of what a conventional system would cost because there are fewer parts, and the Vision-Sciences integrated processor is much cheaper than a conventional video system. Conventional endoscopy requires a dedicated facility and staff for reprocessing, including ventilation for the toxic chemicals that are used during the reprocessing procedure, not to mention the higher frequency of repairing conventional endoscopes. The Vision-Sciences' endoscopy procedure comprises only three easy steps, no toxic chemicals, no special training is required, and the process can be completed in 10 minutes versus 27 steps and over 45 minutes in conventional procedures.
TWST: Now, your technology features something called zero incidences of cross-contamination. Explain this issue further and why your technology represents this solution to an existing problem.
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
